We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down
Read MoreHide Full Article
Pacira BioSciences, Inc. (PCRX - Free Report) announced that it received a Paragraph IV Certification notice letter, which stated that New Jersey-based eVenus Pharmaceutical Laboratories, Inc. has submitted an abbreviated new drug application (“ANDA”) to the FDA, seeking authorization for the manufacturing and marketing of a generic version of Pacira’s flagship product, Exparel (bupivacaine liposome injectable suspension) in the United States. The company is currently assessing the notice letter.
Pacira has 45 days to begin a patent infringement lawsuit against eVenus. The company remains focused to defend its intellectual property rights, owing to Exparel.
Shares of Pacira were down 13.2% on Monday, following the news announcement. The stock has dipped 17.4% so far this year compared with the industry’s decline of 15.6%.
Image Source: Zacks Investment Research
We remind investors that Exparel is a liposome injection of bupivacaine, which is indicated for a single-dose administration into the surgical site to produce postsurgical analgesia for patients in the United States.
Exparel net product sales were $244.7 million in the first six months of 2021, reflecting a year-over-year increase of 40.4%.
In March 2021, the FDA approved Pacira’s supplemental new drug application seeking approval of Exparel for use in children aged six years and above.
In November 2020, the European Commission granted marketing authorization to Exparel as a brachial plexus block or femoral nerve block for the treatment of post-operative pain in adults and as a field block for the treatment of somatic post-operative pain from small to medium-sized surgical wounds in adults. The company expects to launch Exparel in Europe in the fourth quarter of 2021. The nod in Europe should drive Exparel sales further.
We note that Pacira’s top line mainly comprises contributions from Exparel. The company remains heavily dependent on Exparel for growth, which accounts for a significant chunk of its revenues. The potential approval and the launch of generics are likely to hurt Exparel’s sales, which, in turn, is expected to adversely impact the company's top line in the future. This is concerning.
Infinity Pharmaceuticals’ loss per share estimates have narrowed 1.7% for 2021 and 1.6% for 2022 over the past 60 days. The stock has soared 52.4% year to date.
Avenue Therapeutics’ loss per share estimates have narrowed 22.2% for 2021 and 73.6% for 2022 over the past 60 days.
Galmed Pharmaceuticals’ loss per share estimates have narrowed 7.7% for 2021 and 5.7% for 2022 over the past 60 days.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down
Pacira BioSciences, Inc. (PCRX - Free Report) announced that it received a Paragraph IV Certification notice letter, which stated that New Jersey-based eVenus Pharmaceutical Laboratories, Inc. has submitted an abbreviated new drug application (“ANDA”) to the FDA, seeking authorization for the manufacturing and marketing of a generic version of Pacira’s flagship product, Exparel (bupivacaine liposome injectable suspension) in the United States. The company is currently assessing the notice letter.
Pacira has 45 days to begin a patent infringement lawsuit against eVenus. The company remains focused to defend its intellectual property rights, owing to Exparel.
Shares of Pacira were down 13.2% on Monday, following the news announcement. The stock has dipped 17.4% so far this year compared with the industry’s decline of 15.6%.
We remind investors that Exparel is a liposome injection of bupivacaine, which is indicated for a single-dose administration into the surgical site to produce postsurgical analgesia for patients in the United States.
Exparel net product sales were $244.7 million in the first six months of 2021, reflecting a year-over-year increase of 40.4%.
In March 2021, the FDA approved Pacira’s supplemental new drug application seeking approval of Exparel for use in children aged six years and above.
In November 2020, the European Commission granted marketing authorization to Exparel as a brachial plexus block or femoral nerve block for the treatment of post-operative pain in adults and as a field block for the treatment of somatic post-operative pain from small to medium-sized surgical wounds in adults. The company expects to launch Exparel in Europe in the fourth quarter of 2021. The nod in Europe should drive Exparel sales further.
We note that Pacira’s top line mainly comprises contributions from Exparel. The company remains heavily dependent on Exparel for growth, which accounts for a significant chunk of its revenues. The potential approval and the launch of generics are likely to hurt Exparel’s sales, which, in turn, is expected to adversely impact the company's top line in the future. This is concerning.
Zacks Rank & Stocks to Consider
Pacira currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same sector are Infinity Pharmaceuticals, Inc. , Avenue Therapeutics, Inc. (ATXI - Free Report) and Galmed Pharmaceuticals Ltd. (GLMD - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Infinity Pharmaceuticals’ loss per share estimates have narrowed 1.7% for 2021 and 1.6% for 2022 over the past 60 days. The stock has soared 52.4% year to date.
Avenue Therapeutics’ loss per share estimates have narrowed 22.2% for 2021 and 73.6% for 2022 over the past 60 days.
Galmed Pharmaceuticals’ loss per share estimates have narrowed 7.7% for 2021 and 5.7% for 2022 over the past 60 days.